AARD Stock Forecast & Price Target

Aardvark Therapeutics Inc. is well-positioned for future growth due to its innovative approach in developing ARD-101, a novel therapeutic targeting a significant unmet need in treating hyperphagia associated with Prader-Willi Syndrome (PWS). The company’s focus on activating Bitter Taste Receptors (TAS2Rs) in the gut may allow for more effective treatment options compared to existing therapies, as it triggers the release of multiple hormones linked to the hyperphagia pathway. Projections estimate ARD-101 could achieve worldwide sales of $1.5 billion by 2033, reflecting strong market potential and anticipated uptake in a space with considerable demand for improved therapeutic solutions.

Aardvark Therapeutics Inc faces significant challenges as it progresses into a Phase 3 clinical trial for its product candidate ARD-101, primarily due to the limitations of its Phase II data, which was derived from a small sample size of 18 patients and generated results from an open-label study design. The potential for inflated screening responses due to caregiver bias raises concerns about the reliability of the reported efficacy metrics, particularly regarding the HQ-CT scores. Furthermore, while the minimal oral bioavailability of ARD-101 suggests low safety concerns, the incomplete understanding of its safety profile, combined with the critical nature of hyperphagia in patient care, compounds the uncertainties surrounding the drug's market viability.